CATALYST trial protocol: a multicentre, open-label, phase II, multiarm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults

Introduction Severe SARS-CoV-2 infection is associated with a dysregulated immune response. Inflammatory monocytes and macrophages are crucial, promoting injurious, proinflammatory sequelae. Immunomodulation is, therefore, an attractive therapeutic strategy and we sought to test licensed and novel c...

Descrición completa

Detalles Bibliográficos

Principais autores:	Dhruv Parekh, Simon Gates, Julian Bion, Tonny Veenith, Matthew Rowland, Tony Whitehouse, Anna Rowe, Pamela Kearns, Benjamin A. Fisher, Daniel Slade, Rowena Sharpe, David R. Thickett, James Scriven, Sarah J. Bowden, Joshua S. Savage, Duncan Richards
Formato:	Artigo
Idioma:	Inglês
Publicado:	BMJ Publishing Group 2021-11-01
Series:	BMJ Open
Acceso en liña:	https://bmjopen.bmj.com/content/11/11/e050202.full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!